# A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

> **NCT05407961** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 90 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY3532226
- **DRUG:** Placebo
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT05407961
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-07
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-01-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407961, "A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05407961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*